Nuveen Asset Management, LLC Gemini Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.22 - $1.73 $98,428 - $139,574	-80,679 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.29 - $3.08 $4,449 - $10,622	3,449 Added 4.47%	80,679 $116,000
Q4 2021 Feb 14, 2022	SELL	$2.39 - $4.0 $17,934 - $30,016	-7,504 Reduced 8.86%	77,230 $228,000
Q3 2021 Nov 12, 2021	BUY	$3.3 - $6.32 $73,791 - $141,321	22,361 Added 35.85%	84,734 $404,000
Q2 2021 Aug 16, 2021	BUY	$6.32 - $14.02 $394,197 - $874,469	62,373 New	62,373 $403,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.